摘要
目的系统评价黄芪注射液治疗慢性心力衰竭的短期疗效和安全性。方法采用Co-chrane协作网系统评价方法,制定文献纳入标准和排除标准,检索CBMdisc、CNKI、PubMed等电子数据库;评价纳入文献质量,对同质研究进行meta分析。结果11项研究被纳入meta分析,慢性心力衰竭患者共1044例,常规药物对照组(对照组)503例,黄芪注射液+常规药物治疗组(治疗组)541例。meta分析显示与常规药物治疗相比,加用黄芪注射液可使总效率提高,差异具有统计学意义[相对危险度(RR)=1.22,95%CI(1.15,1.29)]。加用黄芪注射液组左室射血分数明显高于常规药物治疗组,差异具有统计学意义[加权均数差(WMD)=6.32,95%CI(4.69,7.95)]。结论现有临床证据表明,加用黄芪注射液治疗慢性心力衰竭可能有效,且无严重的不良反应。但由于本系统评价所纳入的文献研究用药时间较短,因未能进行较长期疗效与安全性的分析,这还需要大量此类文献的支持。
Objective To review the short-term effect and safety of Huangqi Injection for treating chornic heart failure （CHF）. Methods The systematic review method of Cochrane Collaboration was used to develop the inclusive and exclusive criteria of the literature, search electric databases including Chinese Biomedical Database （CBMdisc） , CNKI and PubMed. The quality of the literature was reviewed and meta analysis was carried out on homogeneous study. Results There were 11 documents included into the meta analysis. Among 1 044 cases of the CHF ,503 were inciuded into the control group treated with routine drugs and 541 were inclued into the treatment group treated with Huangqi Injection and routine drugs. The difference was significant statistically[ RR = 1.22, 95% CI （1.15,1.29）]. In the treatment group the left ventricular ejection fraction （LVEF） was significantly higher than that in the control group. The difference was significant statistically [ WMD = 6.32, 95 % CI （4.69, 7.95 ） ]. Conclusion The existing data indicate that Huangqi Injection is effective to CHF without serious adverse reaction. Because the drug administration time was shorter in the literature included in this systematic review, the analysis on long-term treatment out- come and safety cannot be carried out, which requests the support of a large of relevant literature.
出处
《中国循证心血管医学杂志》
2009年第2期78-81,共4页
Chinese Journal of Evidence-Based Cardiovascular Medicine
基金
天津市自然科学基金资助项目(07JCZDJC08700)
关键词
心力衰竭
黄芪注射液
治疗结果
系统评价
Heart failure
Huangqi injection
Treatment outcome
Systematic assessment
